{{FA}}
{{Infobox gene}}
'''血管紧张素转化酶2'''（{{lang-en|Angiotensin-converting enzyme 2}}，{{lang|en|'''ACE2'''}}；人類的ACE2常被稱為'''hACE2'''<ref name="Ennaji_2019">{{cite book | vauthors = Kasmi Y, Khataby K, Souiri A | chapter = Coronaviridae: 100,000 Years of Emergence and Reemergence | chapter-url = https://books.google.com/books?id=4l6wDwAAQBAJ&pg=PA135 | veditors = Ennaji MM | title = Emerging and Reemerging Viral Pathogens | volume = Volume 1: Fundamental and Basic Virology Aspects of Human, Animal and Plant Pathogens | date = 2019 | publisher = Elsevier | isbn = 978-0-12-819400-3 | page = 135 | access-date = 2021-03-04 | archive-date = 2020-07-24 | archive-url = https://web.archive.org/web/20200724223158/https://books.google.com/books?id=4l6wDwAAQBAJ&pg=PA135 | dead-url = no }}</ref>）在[[人類基因組|人類基因組]]中由[[X染色體|X染色體]]上的[[基因|基因]]編碼，是一種表現於[[肺|肺]]、[[動脈|動脈]]、[[心臟|心臟]]、[[腎臟|腎臟]]與[[腸道|腸道]]等組織[[細胞|細胞]]表面的[[膜蛋白|膜蛋白]]，為[[血管紧张素Ⅰ转化酶|血管紧张素Ⅰ转化酶]]（ACE）的一個{{tsl|en|Homology (biology)|旁系同源體}}。

ACE2有切割[[多肽|多肽]]的功能，其多肽酶[[結構域|結構域]]位於[[細胞膜|細胞膜]]外側，一般在細胞膜上作用，可被{{le|脫落酶|sheddase}}切割後脫離細胞、自組織間移除。ACE2可分別將[[血管紧张素#血管紧张素I|血管紧张素I]]和[[血管紧张素#血管紧张素II|血管紧张素II]]轉化为[[血管收縮素(1-9)|血管收縮素(1-9)]]和{{le|血管收縮素(1-7)|Angiotensin (1-7)}}<ref name="pmid10969042"/><ref name="pmid17049503">{{cite journal en | author = Keidar S, Kaplan M, Gamliel-Lazarovich A | title = ACE2 of the heart: From angiotensin I to angiotensin (1-7) | journal = Cardiovasc Res. | volume = 73 | issue = 3 | pages = 463-9 | year = 2007 | pmid = 17049503 | doi =  | issn =  | url = http://cardiovascres.oxfordjournals.org/cgi/content/full/73/3/463 | access-date = 2008-12-11 | archive-date = 2009-01-23 | archive-url = https://web.archive.org/web/20090123071512/http://cardiovascres.oxfordjournals.org/cgi/content/full/73/3/463 | dead-url = no }}</ref>，因而在心血管組織中有抗氧化與[[抗炎性|抗發炎]]等功能，在[[肺臟|肺臟]]中可避免肺組織的損傷，在[[骨骼肌|骨骼肌]]中或许能抑制肌肉纖維化。ACE2的表現可緩解許多心血管疾病的症狀，其表現量的下降則與這些疾病有相關性，有研究嘗試開發[[體外|體外]]合成的人重組ACE2（rhACE2）為這些疾病的一種藥物。除切割多肽外，ACE2還有若干和多肽酶無關的功能。

ACE2还被[[SARS-CoV|SARS-CoV]]、[[嚴重急性呼吸系統綜合症冠狀病毒2型|SARS-CoV-2]]（屬[[乙型冠狀病毒屬|乙型冠狀病毒]]）和[[人類冠狀病毒NL63|人類冠狀病毒NL63]]（屬[[甲型冠狀病毒屬|甲型冠狀病毒]]）等[[冠狀病毒|冠狀病毒]]用作感染細胞的[[受体_(生物化学)|受体]]<ref name="pmid16339739">{{cite journal en| author = Weiss SR, Navas-Martin S | title = Angiotensin-converting enzyme 2--a new cardiac regulator | url = https://archive.org/details/sim_microbiology-and-molecular-biology-reviews_2005-12_69_4/page/635 | journal = Microbiol Mol Biol Rev. | volume = 69 | issue = 4 | pages = 635-64 | year = 2005 | pmid = 16339739 | doi =  | issn = }}</ref>，這些病毒刺突蛋白的受体结合域<ref>{{cite journal|url=http://journals.im.ac.cn/html/wswxtbcn/2017/10/tb17102452.htm|title=冠状病毒S蛋白及其受体的结构和功能|author=沈媚, 陈冰清, 于瑞嵩, 朱于敏, 李震|journal=微生物学通报|year=2017|volume=44|issue=10|page=2452-2462}}</ref>（RBD，receptor binding domain）可結合ACE2，進而使病毒進入細胞內。三種病毒的RBD均與ACE2的相同區域結合，但NL63病毒的RBD結構和另兩者差異較大，與ACE2的結合應為[[趨同演化|趨同演化]]的結果，且結合力較另外兩種病毒弱。[[SARSr-CoV|SARS相關病毒]]也並非皆以ACE2為感染細胞的受體，SARS-CoV-2支系的共祖可能具有和ACE2結合的能力，此支系的病毒又與SARS-CoV支系的病毒發生重組，使部分SARS-CoV相關病毒也獲得此能力。

==結構==
血管紧张素转化酶2（ACE2）最早於2000年自[[cDNA基因庫|cDNA基因庫]]中被發現，為[[血管紧张素Ⅰ转化酶|血管紧张素转化酶]]（ACE）第一個被發現的{{tsl|en|Homology (biology)|旁系同源體}}<ref name="pmid10969042">{{cite journal| author=Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N | display-authors=etal| title=A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. | journal=Circ Res | year= 2000 | volume= 87 | issue= 5 | pages= E1-9 | pmid=10969042 | doi=10.1161/01.res.87.5.e1 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10969042}}</ref>，ACE2的[[基因|基因]]位於人類基因組中的[[X染色體|X染色體]]，包括18個[[外顯子|外顯子]]，編碼的蛋白由805個[[胺基酸|胺基酸]]組成，與ACE的胺基酸序列相似度為42%<ref name="pmid15109615"/>，是一個帶有[[鋅|鋅離子]]的[[金屬蛋白|金屬蛋白]]，屬{{tsl|en|Bitopic protein|單次跨膜蛋白}}（第一型膜蛋白），其[[N端|N端]][[結構域|結構域]]為一M2多肽酶，位於[[細胞膜|細胞膜]]外側，可再細分為I與II兩個子結構域（由一個[[α螺旋|α螺旋]]相連）<ref name="pmid14754895"/>；[[C端|C端]]則與另一種名為collectrin的蛋白同源，包括疏水的跨膜結構域和一個{{le|胺基酸轉運體|Amino acid transporter}}結構域，位於細胞內<ref name = "Turner_2015">{{cite book | first1 = Anthony J. | last1 = Turner | chapter = Chapter 25: ACE2 Cell Biology, Regulation, and Physiological Functions | veditors = Unger T, Ulrike M, Steckelings UM, dos Santos RA | title = The Protective Arm of the Renin Angiotensin System (RAS): Functional Aspects and Therapeutic Implications | date = 2015 | pages = 185–189 | doi = 10.1016/B978-0-12-801364-9.00025-0 | isbn = 978-0-12-801364-9 | publisher = Academic Press }}</ref>。

ACE2因有跨膜區域而造成其結構測定的困難，過去僅知其N端多肽酶的結構，直到2020年科學家才用[[低溫電子顯微鏡|低溫電子顯微鏡]]測出了與另一蛋白{{tsl|en|Sodium-dependent neutral amino acid transporter B(0)AT1|SLC6A19|B<sup>0</sup>AT1}}結合狀態的完整ACE2結構，發現兩個ACE2和兩個B<sup>0</sup>AT1組成一複合體，複合體中兩個ACE2有交互作用，B<sup>0</sup>AT1間則無交互作用，僅與鄰近的ACE2作用，因此研究人員推測細胞膜上的ACE2也可能會形成二聚體<ref name="pmid33231620">{{cite journal | author=Yamamoto K, Takeshita H, Rakugi H | title=ACE2, angiotensin 1-7 and skeletal muscle: review in the era of COVID-19. | journal=Clin Sci (Lond) | year=2020 | volume=134 | issue=22 | pages=3047-3062 | pmid=33231620 | doi=10.1042/CS20200486 | pmc=7687025 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=33231620 | access-date=2021-03-04 | archive-date=2021-03-04 | archive-url=https://web.archive.org/web/20210304054506/https://portlandpress.com/clinsci/article/134/22/3047/227029/ACE2-angiotensin-1-7-and-skeletal-muscle-review-in | dead-url=no }}</ref><ref name="pmid32132184">{{cite journal | author=Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q | title=Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. | journal=Science | year=2020 | volume=367 | issue=6485 | pages=1444-1448 | pmid=32132184 | doi=10.1126/science.abb2762 | pmc=7164635 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32132184 | access-date=2021-03-04 | archive-date=2021-03-04 | archive-url=https://web.archive.org/web/20210304054506/https://science.sciencemag.org/content/367/6485/1444.long | dead-url=no }}</ref>。

===切割機理===
ACE2的[[活性位點|活性位點]]有一個鋅離子（位於多肽酶的子結構域I），和ACE2的兩個[[組胺酸|組胺酸]]、一個[[麩胺酸|麩胺酸]]與一個[[水|水]]分子[[錯合物|錯合]]，切割多肽時，錯合的水分子作為一[[親核基|親核基]]，進攻多肽的[[羰基|羰基]]，形成[[四面體形分子構型|四面體形]]的中間產物，並將質子轉移到麩胺酸上，此時組胺酸上的[[氫離子|氫離子]]轉移到要被切除的胺基酸之胺基上，隨後[[肽鍵|肽鍵]]斷裂，此胺基酸作為[[離去基|離去基]]從中間產物脫離，並從麩胺酸處獲得氫離子<ref name="pmid14754895">{{cite journal| author=Towler P, Staker B, Prasad SG, Menon S, Tang J, Parsons T | display-authors=etal| title=ACE2 X-ray structures reveal a large hinge-bending motion important for inhibitor binding and catalysis. | journal=J Biol Chem | year= 2004 | volume= 279 | issue= 17 | pages= 17996-8007 | pmid=14754895 | doi=10.1074/jbc.M311191200 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=14754895 }}</ref>。

[[File:Mechanism_of_ACE2.svg|475px]]

==表現組織==
人體幾乎所有器官組織都有表現[[血管紧张素转化酶|血管紧张素转化酶]]（ACE），而血管紧张素转化酶2（ACE2）則表現於[[肺泡|II型肺泡細胞]]、[[小腸|小腸]]{{tsl|en|enterocyte|腸上皮細胞}}、[[血管內皮細胞|血管內皮細胞]]、[[血管平滑肌|血管平滑肌]]細胞、[[腎臟|腎臟]]上皮細胞等，腦部許多[[神經元|神經元]]與[[神經膠細胞|膠細胞]]可能也有表現ACE2<ref name="pmid15109615"/><ref>{{cite journal |last1=Kabbani |first1=Nadine |last2=Olds |first2=James L |title=Does COVID19 infect the brain? If so, smokers might be at a higher risk |journal=Molecular Pharmacology |date=1 April 2020 |volume=97 |issue=5 |pages=351–353 |doi=10.1124/molpharm.120.000014|pmid=32238438 |pmc=7237865 }}</ref>。多數組織中ACE2的[[轉錄|轉錄]]都是由一個較接近其基因的[[啟動子|啟動子]]起始，但肺臟中ACE2基因的轉錄多起始於一個較遠的啟動子，兩啟動子轉錄出的[[mRNA|mRNA]][[方向性_(分子生物學)|5端]]序列稍有不同<ref name="pmid24100303">{{cite journal | author=Pedersen KB, Chhabra KH, Nguyen VK, Xia H, Lazartigues E | title=The transcription factor HNF1α induces expression of angiotensin-converting enzyme 2 (ACE2) in pancreatic islets from evolutionarily conserved promoter motifs. | journal=Biochim Biophys Acta | year=2013 | volume=1829 | issue=11 | pages=1225-35 | pmid=24100303 | doi=10.1016/j.bbagrm.2013.09.007 | pmc=3838857 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24100303 | access-date=2021-03-04 | archive-date=2021-03-04 | archive-url=https://web.archive.org/web/20210304054506/https://www.sciencedirect.com/science/article/abs/pii/S1874939913001405?via%3Dihub | dead-url=no }}</ref><ref name="pmid33057007"/>。

==功能==
===切割多肽===
{{enzyme
| Name =血管紧张素转化酶2
|Systematic_name = Angiotensin-converting enzyme 2
| Acronym = ACE2
| EC_number = 3.4.17.23
| CAS_number =
| IUBMB_EC_number =
| GO_code =
| width =
| caption =
|align=left
}}
血管紧张素转化酶2主要的功能是與[[血管紧张素Ⅰ转化酶|血管紧张素Ⅰ转化酶]]（ACE）拮抗，ACE可將無活性的[[血管收縮素|血管收縮素Ⅰ]]切割成[[血管收縮素II|血管收縮素II]]，後者可促進[[抗利尿激素|抗利尿激素]]與[[醛固酮|醛固酮]]的分泌，以及刺激血管平滑肌收縮，使[[血壓|血壓]]上升；ACE2則分解血管收縮素Ⅰ和血管收縮素II以抑制其作用，將其[[C端|C端]]的胺基酸移除，分別將前者轉化成[[血管收縮素(1-9)|血管收縮素(1-9)]]，將後者轉化成{{le|血管收縮素(1-7)|Angiotensin (1-7)}}{{Notetag|1=ACE2將血管收縮素ⅠI切割為血管收縮素(1-7)，是控制組織間血管收縮素濃度的主要蛋白，但還有另一種蛋白{{le|中性肽鏈內切酶|Neprilysin}}可直接將血管收縮素Ⅰ切割為血管收縮素(1-7)<ref name="pmid33231620"/><ref name="pmid27649628">{{cite journal| author=Domenig O, Manzel A, Grobe N, Königshausen E, Kaltenecker CC, Kovarik JJ | display-authors=etal| title=Neprilysin is a Mediator of Alternative Renin-Angiotensin-System Activation in the Murine and Human Kidney. | journal=Sci Rep | year= 2016 | volume= 6 | issue=  | pages= 33678 | pmid=27649628 | doi=10.1038/srep33678 | pmc=5030486 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27649628  }}</ref>。}}，其中切割血管收縮素II比切割血管收縮素I的能力高出許多，切割的產物中，血管收縮素(1-9)的功能不明，血管收縮素(1-7)則可刺激[[一氧化氮|一氧化氮]]合成、抑制{{le|MAPK/ERK途徑|MAPK/ERK pathway}}與{{le|TGFβ途徑|TGF beta signaling pathway}}、以及抑制[[活性氧類|活性氧物質]]的生成，因此在心血管組織中有抗氧化與[[抗炎性|抗發炎]]等功能<ref name="pmid15109615">{{cite journal | author=Burrell LM, Johnston CI, Tikellis C, Cooper ME | title=ACE2, a new regulator of the renin-angiotensin system. | journal=Trends Endocrinol Metab | year=2004 | volume=15 | issue=4 | pages=166-9 | pmid=15109615 | doi=10.1016/j.tem.2004.03.001 | pmc=7128798 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=15109615 | access-date=2021-03-04 | archive-date=2021-03-04 | archive-url=https://web.archive.org/web/20210304054508/https://www.cell.com/trends/endocrinology-metabolism/fulltext/S1043-2760(04)00056-6?_returnURL=https%3A%2F%2Flinkinghub.elsevier.com%2Fretrieve%2Fpii%2FS1043276004000566%3Fshowall%3Dtrue | dead-url=no }}</ref><ref name="pmid33231620"/>。許多研究結果顯示ACE2表現量的下降與數種[[心血管疾病|心血管疾病]]有相關性<ref name="pmid17703127">{{cite journal | author=Raizada MK, Ferreira AJ | title=ACE2: a new target for cardiovascular disease therapeutics. | journal=J Cardiovasc Pharmacol | year=2007 | volume=50 | issue=2 | pages=112-9 | pmid=17703127 | doi=10.1097/FJC.0b013e3180986219 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17703127 | access-date=2021-03-04 | archive-date=2021-03-04 | archive-url=https://web.archive.org/web/20210304054522/https://journals.lww.com/cardiovascularpharm/Fulltext/2007/08000/ACE2__A_New_Target_for_Cardiovascular_Disease.3.aspx | dead-url=no }}</ref>。

[[肺泡|肺泡]]細胞表現的ACE2有保護肺組織的功能。血管收縮素II可促進肺泡細胞[[細胞凋亡|凋亡]]與肺纖維化<ref name="pmid21665960">{{cite journal | author=Uhal BD, Li X, Xue A, Gao X, Abdul-Hafez A | title=Regulation of alveolar epithelial cell survival by the ACE-2/angiotensin 1-7/Mas axis. | journal=Am J Physiol Lung Cell Mol Physiol | year=2011 | volume=301 | issue=3 | pages=L269-74 | pmid=21665960 | doi=10.1152/ajplung.00222.2010 | pmc=3174737 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=21665960 | access-date=2021-03-04 | archive-date=2021-03-04 | archive-url=https://web.archive.org/web/20210304054509/https://journals.physiology.org/doi/full/10.1152/ajplung.00222.2010?rfr_dat=cr_pub%3Dpubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org | dead-url=no }}</ref>，因此ACE2將其分解可保護肺免於損傷<ref name="pmid32582574"/>，加上血管收縮素(1-7)可與{{le|MAS1|Mas}}受體結合，啟動下游反應以抑制血管收縮素II的作用<ref name="pmid32582574">{{cite journal| author=Samavati L, Uhal BD| title=ACE2, Much More Than Just a Receptor for SARS-COV-2. | journal=Front Cell Infect Microbiol | year= 2020 | volume= 10 | issue=  | pages= 317 | pmid=32582574 | doi=10.3389/fcimb.2020.00317 | pmc=7294848 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32582574 }}</ref><ref name="pmid26637635">{{cite journal| author=Gopallawa I, Uhal BD| title=Angiotensin-(1-7)/mas inhibits apoptosis in alveolar epithelial cells through upregulation of MAP kinase phosphatase-2. | journal=Am J Physiol Lung Cell Mol Physiol | year= 2016 | volume= 310 | issue= 3 | pages= L240-8 | pmid=26637635 | doi=10.1152/ajplung.00187.2015 | pmc=4888557 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=26637635 }}</ref>。

在[[骨骼肌|骨骼肌]]中，血管收縮素II與血管收縮素(1-7)均有重要功能。血管收縮素II透過多種途徑降低肌肉蛋白質的合成，包括抑制[[蛋白激酶B|Akt]]－{{le|mTOR}}途徑、促進{{tsl|en|FBXO32|肌萎缩素1}}與{{tsl|en|TRIM63|肌环指蛋白1|}}的合成、生成[[活性氧類|活性氧物質]]而活化[[胱天蛋白酶|胱天蛋白酶]]途徑使[[細胞凋亡|細胞凋亡]]等，肌肉蛋白合成與分解的失衡會造成{{le|肌萎缩|muscular atrophy}}、肌[[纖維化|纖維化]]等症狀<ref name="pmid25764065">{{cite journal| author=Cabello-Verrugio C, Morales MG, Rivera JC, Cabrera D, Simon F| title=Renin-angiotensin system: an old player with novel functions in skeletal muscle. | journal=Med Res Rev | year= 2015 | volume= 35 | issue= 3 | pages= 437-63 | pmid=25764065 | doi=10.1002/med.21343 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25764065 }} </ref><ref name="pmid31273946">{{cite journal| author=Winslow MA, Hall SE| title=Muscle wasting: A review of exercise, classical and non-classical RAS axes. | journal=J Cell Mol Med | year= 2019 | volume= 23 | issue= 9 | pages= 5836-5845 | pmid=31273946 | doi=10.1111/jcmm.14412 | pmc=6714228 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=31273946 }}</ref>，因此將血管收縮素II被轉化成血管收縮素(1-7)可停止其作用，且後者還可與{{le|MAS1|Mas}}受體結合，活化另一條反應途徑而抑制肌纖維化<ref name="pmid33231620"/><ref name="pmid25208653">{{cite journal | author=Morales MG, Abrigo J, Meneses C, Cisternas F, Simon F, Cabello-Verrugio C | title=Expression of the Mas receptor is upregulated in skeletal muscle wasting. | journal=Histochem Cell Biol | year=2015 | volume=143 | issue=2 | pages=131-41 | pmid=25208653 | doi=10.1007/s00418-014-1275-1 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=25208653 | access-date=2021-03-04 | archive-date=2021-03-04 | archive-url=https://web.archive.org/web/20210304054734/https://link.springer.com/article/10.1007/s00418-014-1275-1 | dead-url=no }}</ref>。相較之下ACE2在骨骼肌的直接影響還有待更多研究闡明，有初步研究結果顯示在萎縮的肌肉組織中，ACE2可能可降低纖維化<ref name="pmid33231620"/><ref name="pmid24695436">{{cite journal | author=Riquelme C, Acuña MJ, Torrejón J, Rebolledo D, Cabrera D, Santos RA | display-authors=etal | title=ACE2 is augmented in dystrophic skeletal muscle and plays a role in decreasing associated fibrosis. | journal=PLoS One | year=2014 | volume=9 | issue=4 | pages=e93449 | pmid=24695436 | doi=10.1371/journal.pone.0093449 | pmc=3973684 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=24695436 | access-date=2021-03-04 | archive-date=2021-03-04 | archive-url=https://web.archive.org/web/20210304054740/https://journals.plos.org/plosone/article?id=10.1371%2Fjournal.pone.0093449 | dead-url=no }}</ref>。

由於ACE2的表現可緩解許多心血管疾病的症狀，有研究嘗試在[[體外|體外]]以細胞株合成ACE2（人重組ACE2；rhACE2）以期作為這些疾病的一種療法<ref name="pmid33057007"/><ref name="Mirabito ColafellaUijl2019">{{cite journal|last1=Mirabito Colafella|first1=Katrina M.|last2=Uijl|first2=Estrellita|last3=Jan Danser|first3=A.H.|title=Interference With the Renin–Angiotensin System (RAS): Classical Inhibitors and Novel Approaches|year=2019|pages=523–530|doi=10.1016/B978-0-12-801238-3.65341-2}}</ref>。

除了切割血管收縮素II外，ACE2還可切割{{le|強啡肽A|Dynorphin A}}、{{tsl|en|apelin-13|apelin|apelin-13}}<ref name="pmid28293165">{{cite journal | author=Yang P, Kuc RE, Brame AL, Dyson A, Singer M, Glen RC | display-authors=etal | title=[Pyr1]Apelin-13(1-12) Is a Biologically Active ACE2 Metabolite of the Endogenous Cardiovascular Peptide [Pyr1]Apelin-13. | journal=Front Neurosci | year=2017 | volume=11 | issue= | pages=92 | pmid=28293165 | doi=10.3389/fnins.2017.00092 | pmc=5329011 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=28293165 | access-date=2021-03-04 | archive-date=2021-03-04 | archive-url=https://web.archive.org/web/20210304054736/https://www.frontiersin.org/articles/10.3389/fnins.2017.00092/full | dead-url=no }}</ref>、apelin-36、去精胺酸[[緩激肽|緩激肽]]（des-Arg(9) bradykinin）、{{le|β-酪啡肽|casomorphin}}等其他多肽，惟其生理意義仍不明<ref name="pmid33057007">{{cite journal | author=Jia H, Yue X, Lazartigues E | title=ACE2 mouse models: a toolbox for cardiovascular and pulmonary research. | journal=Nat Commun | year=2020 | volume=11 | issue=1 | pages=5165 | pmid=33057007 | doi=10.1038/s41467-020-18880-0 | pmc=7560817 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=33057007 | access-date=2021-03-04 | archive-date=2021-03-04 | archive-url=https://web.archive.org/web/20210304054744/https://www.nature.com/articles/s41467-020-18880-0 | dead-url=no }}</ref><ref name="pmid16079870">{{cite journal| author=Nicholls J, Peiris M| title=Good ACE, bad ACE do battle in lung injury, SARS. | journal=Nat Med | year= 2005 | volume= 11 | issue= 8 | pages= 821-2 | pmid=16079870 | doi=10.1038/nm0805-821 | pmc=7095949 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16079870 }} </ref>。

===其他===
除了切割多肽外，ACE2還有些與其蛋白酶活性無關的功能。有研究顯示ACE2可與[[整合素|整合素]]結合，有助於{{le|細胞黏附|cell adhesion}}<ref name="pmid33231620" /><ref name="pmid/10.1371/journal.pone.0034747">{{cite journal | author= Schmoldt A, Benthe HF, Haberland G | title= Digitoxin metabolism by rat liver microsomes. | journal= Biochem Pharmacol | year= 1975 | volume= 24 | issue= 17 | pages= 1639-41 | doi= 10.1371/journal.pone.0034747 | pmc=  | url= https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=10 | access-date= 2021-03-04 | archive-date= 2021-03-04 | archive-url= https://web.archive.org/web/20210304054743/https://www.sciencedirect.com/science/article/abs/pii/0006295275900945?via%3Dihub | dead-url= no }}</ref>。此外ACE2還參與了另一蛋白{{tsl|en|Sodium-dependent neutral amino acid transporter B(0)AT1|SLC6A19|B<sup>0</sup>AT1}}的[[膜囊泡運輸|膜囊泡運輸]]過程，為其[[伴護蛋白|伴護蛋白]]，與B<sup>0</sup>AT1形成一複合體，協助將其轉運至[[細胞膜|細胞膜]]上<ref name="pmid32132184"/>。

==移除==
ACE2的跨膜結構域可被一種稱為{{le|金屬蛋白酶17|MMP17}}（MMP17）的{{le|脱落酶|sheddase}}切割，將其胞外部分釋放到血液中，進而從組織間移除<ref>{{cite journal | vauthors = Lambert DW, Yarski M, Warner FJ, Thornhill P, Parkin ET, Smith AI, Hooper NM, Turner AJ | display-authors = 6 | title = Tumor necrosis factor-alpha convertase (ADAM17) mediates regulated ectodomain shedding of the severe-acute respiratory syndrome-coronavirus (SARS-CoV) receptor, angiotensin-converting enzyme-2 (ACE2) | journal = The Journal of Biological Chemistry | volume = 280 | issue = 34 | pages = 30113–9 | date = August 2005 | pmid = 15983030 | doi = 10.1074/jbc.M505111200  }}</ref><ref>{{cite journal | vauthors = Patel VB, Clarke N, Wang Z, Fan D, Parajuli N, Basu R, Putko B, Kassiri Z, Turner AJ, Oudit GY | display-authors = 6 | title = Angiotensin II induced proteolytic cleavage of myocardial ACE2 is mediated by TACE/ADAM-17: a positive feedback mechanism in the RAS | journal = Journal of Molecular and Cellular Cardiology | volume = 66 | pages = 167–76 | date = January 2014 | pmid = 24332999 | doi = 10.1016/j.yjmcc.2013.11.017 }}</ref>，此過程受到許多調控，例如有一種[[鈣調蛋白|鈣調蛋白]]可與ACE2結合以抑制MMP17的切割<ref name="pmid18070603">{{cite journal| author=Lambert DW, Clarke NE, Hooper NM, Turner AJ| title=Calmodulin interacts with angiotensin-converting enzyme-2 (ACE2) and inhibits shedding of its ectodomain. | journal=FEBS Lett | year= 2008 | volume= 582 | issue= 2 | pages= 385-90 | pmid=18070603 | doi=10.1016/j.febslet.2007.11.085 | pmc=7094239 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=18070603 }} </ref>，[[血管收縮素II|血管收縮素II]]也可促進MMP17的活性，把會將其分解的ACE2移除<ref name="pmid20188673">{{cite journal| author=Xu P, Derynck R| title=Direct activation of TACE-mediated ectodomain shedding by p38 MAP kinase regulates EGF receptor-dependent cell proliferation. | journal=Mol Cell | year= 2010 | volume= 37 | issue= 4 | pages= 551-66 | pmid=20188673 | doi=10.1016/j.molcel.2010.01.034 | pmc=4240279 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=20188673 }} </ref>，另外許多病理狀況、發炎反應也可促進MMP17對ACE2的切割。脫落酶的切割會造成心血管組織中ACE2的流失、血液中ACE2的濃度升高，因此後者可當作[[心臟衰竭|心臟衰竭]]、[[心房顫動|心房顫動]]、[[動脈粥樣硬化|動脈粥樣硬化]]、[[慢性腎臟病|慢性腎臟病]]、[[心肌梗塞|心肌梗塞]]與[[中風|中風]]等多種疾病的[[生物標記|生物標記]]<ref name="pmid33231620"/><ref name="pmid27081112">{{cite journal | author=Patel VB, Zhong JC, Grant MB, Oudit GY | title=Role of the ACE2/Angiotensin 1-7 Axis of the Renin-Angiotensin System in Heart Failure. | journal=Circ Res | year=2016 | volume=118 | issue=8 | pages=1313-26 | pmid=27081112 | doi=10.1161/CIRCRESAHA.116.307708 | pmc=4939482 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=27081112 | access-date=2021-03-04 | archive-date=2021-03-04 | archive-url=https://web.archive.org/web/20210304054734/https://www.ahajournals.org/doi/10.1161/CIRCRESAHA.116.307708?url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org&rfr_dat=cr_pub%3Dpubmed& | dead-url=no }}</ref>。

==冠狀病毒受體==
[[File:Microorganisms-08-01259-g001.webp|thumb]]以ACE2為受體感染細胞]]
血管紧张素转化酶2被許多[[冠狀病毒|冠狀病毒]]用來當作感染細胞的受體，包括造成[[普通感冒|普通感冒]]的[[人類冠狀病毒NL63|人類冠狀病毒NL63]]（屬[[甲型冠狀病毒屬|甲型冠狀病毒]]）<ref name="NCBI_ACE2">{{cite web |title=Gene: ACE2, angiotensin I converting enzyme 2 |work=[[National_Center_for_Biotechnology_Information|National Center for Biotechnology Information]] (NCBI) |publisher=U.S. National Library of Medicine |date=2020-02-28 |url=https://www.ncbi.nlm.nih.gov/gene/59272 |accessdate=2021-02-22 |archive-date=2014-12-24 |archive-url=https://web.archive.org/web/20141224155544/https://www.ncbi.nlm.nih.gov/gene/59272 |dead-url=no }}</ref>、造成[[SARS|SARS]]的[[SARS-CoV|SARS-CoV]]<ref name="Fehr_2015">{{cite book | vauthors = Fehr AR, Perlman S | title = Coronaviruses | chapter = Coronaviruses: an overview of their replication and pathogenesis | series = Methods in Molecular Biology | volume = 1282 | pages = 1–23 | year = 2015 | pmid = 25720466 | pmc = 4369385 | doi = 10.1007/978-1-4939-2438-7_1 | publisher = Springer New York | isbn = 978-1-4939-2437-0 | quote = Many α-coronaviruses utilize aminopeptidase N (APN) as their receptor, SARS-CoV and HCoV-NL63 use angiotensin-converting enzyme 2 (ACE2) as their receptor, MHV enters through CEACAM1, and the recently identified MERS-CoV binds to dipeptidyl-peptidase 4 (DPP4) to gain entry into human cells (See Table 1 for a list of known CoV receptors). }}</ref><ref>{{cite journal | vauthors = Li F | title = Receptor recognition and cross-species infections of SARS coronavirus | journal = Antiviral Research | volume = 100 | issue = 1 | pages = 246–54 | date = October 2013 | pmid = 23994189 | pmc = 3840050 | doi = 10.1016/j.antiviral.2013.08.014 }}</ref>和造成[[2019冠狀病毒病|2019冠狀病毒病]]的[[SARS-CoV-2|SARS-CoV-2]]（屬[[乙型冠狀病毒屬|乙型冠狀病毒]]）<ref>{{cite web |title=What are the official names of the disease and the virus that causes it? |url=https://www.who.int/news-room/q-a-detail/q-a-coronaviruses |website=Q&A on coronaviruses |publisher=World Health Organization |access-date=22 February 2020 |archive-url=https://web.archive.org/web/20200305015146/https://www.who.int/news-room/q-a-detail/q-a-coronaviruses |archive-date=2020-03-05 |dead-url=no }}</ref>，這些病毒刺突蛋白S1結構域中的[[受體結合結構域|受體結合結構域]]（receptor binding domain；RBD）和ACE2胞外的區域結合後，刺突蛋白可能被細胞表面的[[跨膜丝氨酸蛋白酶2|跨膜丝氨酸蛋白酶2]]（TMPRSS2）切割，促使病毒外膜和宿主[[細胞膜|細胞膜]]融合而讓病毒進入[[細胞質|細胞質]]<ref>{{Cite journal|last1=Akhmerov Akbarshakh|last2=Marban Eduardo|title=COVID-19 and the Heart|journal=Circulation Research|year=2020|volume=0|issue=10|pages=1443–1455|doi=10.1161/CIRCRESAHA.120.317055|pmid=32252591|pmc=7188058}}</ref>；此外SARS-CoV與SARS-CoV-2<ref name="pmid32221306">{{cite journal | author=Ou X, Liu Y, Lei X, Li P, Mi D, Ren L | display-authors=etal | title=Characterization of spike glycoprotein of SARS-CoV-2 on virus entry and its immune cross-reactivity with SARS-CoV. | journal=Nat Commun | year=2020 | volume=11 | issue=1 | pages=1620 | pmid=32221306 | doi=10.1038/s41467-020-15562-9 | pmc=7100515 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32221306 | access-date=2021-03-04 | archive-date=2021-03-04 | archive-url=https://web.archive.org/web/20210304054737/https://www.nature.com/articles/s41467-020-15562-9 | dead-url=no }}</ref>還可能在不被TMPRSS2切割的情況下，與ACE2受體一起藉由[[內吞作用|內吞作用]]進入細胞，隨後其刺突蛋白在[[溶體|溶體]]中被{{le|組織蛋白酶|Cathepsin}}切割後，再從溶體進入細胞質中<ref name="Wang_2008">{{cite journal | vauthors = Wang H, Yang P, Liu K, Guo F, Zhang Y, Zhang G, Jiang C | title = SARS coronavirus entry into host cells through a novel clathrin- and caveolae-independent endocytic pathway | journal = Cell Research | volume = 18 | issue = 2 | pages = 290–301 | date = February 2008 | pmid = 18227861 | pmc = 7091891 | doi = 10.1038/cr.2008.15 }}</ref><ref name="Millet_2018">{{cite journal | vauthors = Millet JK, Whittaker GR | title = Physiological and molecular triggers for SARS-CoV membrane fusion and entry into host cells | journal = Virology | volume = 517 | pages = 3–8 | date = April 2018 | pmid = 29275820 | pmc = 7112017 | doi = 10.1016/j.virol.2017.12.015 }}</ref><ref name="pmid16339146">{{cite journal | author=Huang IC, Bosch BJ, Li F, Li W, Lee KH, Ghiran S | display-authors=etal | title=SARS coronavirus, but not human coronavirus NL63, utilizes cathepsin L to infect ACE2-expressing cells. | journal=J Biol Chem | year=2006 | volume=281 | issue=6 | pages=3198-203 | pmid=16339146 | doi=10.1074/jbc.M508381200 | pmc= | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=16339146 | access-date=2021-03-04 | archive-date=2021-03-04 | archive-url=https://web.archive.org/web/20210304054746/https://www.jbc.org/article/S0021-9258(20)81705-0/fulltext | dead-url=no }}</ref>。

SARS-CoV與SARS-CoV-2的RBD結構相似，胺基酸序列相似度為72%，SARS-CoV的RBD和ACE2結合時，與其直接接觸的胺基酸共有16個，其中8個位點在SARS-CoV-2中為對應相同胺基酸，另外8個則不同，因此兩者與ACE2結合的機制略有差異<ref name="pmid32081428"/>。SARS-CoV-2的RBD有6個[[胺基酸|胺基酸]]為與ACE2結合所需，包括[[白胺酸|白胺酸]]455、[[苯丙胺酸|苯丙胺酸]]486、[[麩醯胺酸|麩醯胺酸]]493、[[絲胺酸|絲胺酸]]494、[[天門冬醯胺|天門冬醯胺]]501與[[酪氨酸|酪氨酸]]505<ref name="pmid32284615">{{cite journal | author=Andersen KG, Rambaut A, Lipkin WI, Holmes EC, Garry RF | title=The proximal origin of SARS-CoV-2. | journal=Nat Med | year=2020 | volume=26 | issue=4 | pages=450-452 | pmid=32284615 | doi=10.1038/s41591-020-0820-9 | pmc=7095063 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32284615 | access-date=2021-03-04 | archive-date=2021-03-04 | archive-url=https://web.archive.org/web/20210304054737/https://www.nature.com/articles/s41591-020-0820-9 | dead-url=no }}</ref>，與ACE2的結合力高於SARS-CoV<ref name="pmid32376634">{{cite journal| author=Shang J, Wan Y, Luo C, Ye G, Geng Q, Auerbach A | display-authors=etal| title=Cell entry mechanisms of SARS-CoV-2. | journal=Proc Natl Acad Sci U S A | year= 2020 | volume= 117 | issue= 21 | pages= 11727-11734 | pmid=32376634 | doi=10.1073/pnas.2003138117 | pmc=7260975 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32376634  }} </ref>。人類冠狀病毒NL63之RBD則與前兩者的結構差異較大，卻能和ACE2的同一區域結合，為[[趨同演化|趨同演化]]的結果，但NL63和ACE2的結合力較弱，可能是其感染症狀較輕微的原因之一<ref name="pmid32081428">{{cite journal| author=Chen Y, Guo Y, Pan Y, Zhao ZJ| title=Structure analysis of the receptor binding of 2019-nCoV. | journal=Biochem Biophys Res Commun | year= 2020 | volume=  | issue=  | pages=  | pmid=32081428 | doi=10.1016/j.bbrc.2020.02.071 | pmc=7092824 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32081428  }} </ref>。

而[[SARSr-CoV|SARS相關病毒]]亦非皆以ACE2為感染細胞的受體，SARSr-CoV中，使用ACE2為受體的病毒株包含SARS-CoV支系的[[果子狸SARS冠狀病毒|果子狸SARS冠狀病毒]]、[[WIV1病毒|WIV1]]、[[SHC014病毒|SHC014]]、[[WIV16病毒|WIV16]]、[[LYRa11病毒|LYRa11]]、Rs4874、Rs7327等（以上病毒的RBD序列可再分成兩支），以及SARS-CoV-2支系的[[RaTG13病毒|RaTG13]]和[[穿山甲冠狀病毒|穿山甲冠狀病毒]]，上述以ACE2為受體的蝙蝠病毒皆是在中國[[雲南省|雲南省]]發現；SARS-CoV支系的[[YNLF_31C病毒與YNLF_34C病毒|YNLF_31C]]、[[YNLF_31C病毒與YNLF_34C病毒|YNLF_34C]]、[[BtKY72|BtKY72]]、[[BM48-31|BM48-31]]、[[16BO133病毒|16BO133]]、[[蝙蝠冠狀病毒HKU3|HKU3]]、[[Rm1病毒|Rm1]]和[[Rf1病毒|Rf1]]等，以及SARS-CoV-2支系的[[RmYN02病毒|RmYN02]]之RBD則應無法與ACE2結合，而是使用其他蛋白作為感染的受體，這些病毒株的RBD大多具有兩段序列缺失，可能因此影響和ACE2結合的能力{{Notetag|1=[[BtKY72|BtKY72]]、[[BM48-31|BM48-31]]等在[[非洲|非洲]]發現的[[SARSr-CoV|SARSr-CoV]]病毒株則不具有這兩段序列缺失，但因此區序列和SARS-CoV、SARS-CoV-2的差異較大，仍應無法和ACE2結合<ref name="WellsLetko2021"/>。}}<ref name="WellsLetko2021"/>。SARSr-CoV中，與ACE2的結合能力應為多次起源，有學者提出SARS-CoV-2支系病毒的共祖可能可和ACE2結合（RmYN02則是後來才喪失了此能力），後來某個SARS-CoV-2支系的病毒曾和SARS-CoV支系的病毒發生重組，造成部分SARS-CoV支系的病毒也獲得了和ACE2結合的能力<ref name="WellsLetko2021">{{cite journal|last1=Wells|first1=H L|last2=Letko|first2=M|last3=Lasso|first3=G|last4=Ssebide|first4=B|last5=Nziza|first5=J|last6=Byarugaba|first6=D K|last7=Navarrete-Macias|first7=I|last8=Liang|first8=E|last9=Cranfield|first9=M|last10=Han|first10=B A|last11=Tingley|first11=M W|last12=Diuk-Wasser|first12=M|last13=Goldstein|first13=T|last14=Johnson|first14=C K|last15=Mazet|first15=J A K|last16=Chandran|first16=K|last17=Munster|first17=V J|last18=Gilardi|first18=K|last19=Anthony|first19=S J|displayauthors=8|title=The evolutionary history of ACE2 usage within the coronavirus subgenus Sarbecovirus |journal=Virus Evolution|year=2021|issn=2057-1577|doi=10.1093/ve/veab007}}</ref>。

==演化==
早期的[[脊索動物|脊索動物]]已具有ACE2，[[海鞘|海鞘]]（[[尾索動物|尾索動物]]）與[[文昌魚|文昌魚]]（[[頭索動物|頭索動物]]）皆尚無[[血管紧张素|血管紧张素]]等[[肾素-血管紧张素系统|肾素-血管紧张素系统]]的多數蛋白，但已具有ACE與ACE2<ref name="pmid22527880"/>。[[脊椎動物|脊椎動物]]（[[魚類|魚類]]、[[兩生類|兩生類]]、[[爬行類|爬行類]]、[[鳥類|鳥類]]與[[哺乳類|哺乳類]]）皆具有ACE2，且其結構的[[保守序列|保守度]]很高<ref name="pmid32081428"/>。此外有些[[細菌|細菌]]（如{{le|野油菜黄单胞菌|Citrus canker}}柑橘致病变种）具有和ACE同源的蛋白，[[體外|體外]]實驗結果顯示其具有將[[血管紧张素#血管紧张素I|血管紧张素I]]切割成[[血管紧张素#血管紧张素II|血管紧张素II]]的能力<ref name="pmid17597310">{{cite journal| author=Rivière G, Michaud A, Corradi HR, Sturrock ED, Ravi Acharya K, Cogez V | display-authors=etal| title=Characterization of the first angiotensin-converting like enzyme in bacteria: Ancestor ACE is already active. | journal=Gene | year= 2007 | volume= 399 | issue= 1 | pages= 81-90 | pmid=17597310 | doi=10.1016/j.gene.2007.05.010 | pmc=7127174 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=17597310  }} </ref>，以各生物中的ACE與ACE2序列製作的[[系統發生樹|系統發生樹]]顯示細菌ACE與海鞘、文昌魚的ACE2關係較為接近，可能是由海鞘的ACE2經[[水平基因轉移|水平基因轉移]]至細菌基因組中<ref name="pmid22527880">{{cite journal| author=Fournier D, Luft FC, Bader M, Ganten D, Andrade-Navarro MA| title=Emergence and evolution of the renin-angiotensin-aldosterone system. | journal=J Mol Med (Berl) | year= 2012 | volume= 90 | issue= 5 | pages= 495-508 | pmid=22527880 | doi=10.1007/s00109-012-0894-z | pmc=3354321 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22527880  }} </ref>。

有研究分析哺乳類的ACE2序列，發現有4%的位點（皆位於具有酵素活性的結構域）正發生[[定向選擇|定向選擇]]<ref name="pmid32520981">{{cite journal| author=Bibiana S O F, Vargas-Pinilla P, Amorim CEG, Sortica VA, Bortolini MC| title=ACE2 diversity in placental mammals reveals the evolutionary strategy of SARS-CoV-2. | journal=Genet Mol Biol | year= 2020 | volume= 43 | issue= 2 | pages= e20200104 | pmid=32520981 | doi=10.1590/1678-4685-GMB-2020-0104 | pmc=7278419 | url=https://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=32520981  }} </ref>。

==参见==
*[[肾素-血管紧张素系统|肾素-血管紧张素系统]]
*[[血管紧张肽I转化酶抑制剂|血管紧张肽I转化酶抑制剂]]
*[[血管紧张素Ⅰ转化酶|血管紧张素Ⅰ转化酶]]
{{portalbar|生物學|分子與細胞生物學|病毒|醫學|2019冠状病毒病}}

==註腳==
{{Notefoot}}

==参考文献==
{{Reflist|3}}

==外部連結==
* {{UCSC gene info|ACE2}}

[[Category:位於人類X染色體的基因|Category:位於人類X染色體的基因]]
[[Category:EC_3.4.17|Category:EC 3.4.17]]
[[Category:單次跨膜蛋白|Category:單次跨膜蛋白]]